This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Sarepta (SRPT) Begins Pivotal Study on DMD Gene Therapy
by Zacks Equity Research
Sarepta (SRPT) is developing its lead gene therapy candidate, SRP-9001, as a potential one-time treatment for DMD.
Glaxo (GSK) Eyes Nod for Triumeq Expanded Use in Pediatric HIV
by Zacks Equity Research
Glaxo (GSK) seeks approval for a new dispersible single-tablet regimen containing dolutegravir to treat children living with HIV.
Pfizer (PFE) Stock Moves -1.19%: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $42.42, marking a -1.19% move from the previous day.
Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Is Pfizer (PFE) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
BioNTech (BNTX) Begins Dosing in mRNA Cancer Vaccine Study
by Zacks Equity Research
BioNTech (BNTX) doses the first patient in a phase II study on its mRNA cancer vaccine candidate, BNT122, in patients with colorectal cancer.
3 Drugmakers in Focus After Merck's Positive COVID-19 Pill Data
by Zacks Equity Research
Here we discuss three other pharma or biotech companies with promising oral drug candidates for treating COVID-19 following Merck's (MRK) announcement of promising clinical data on its oral therapy.
Vaccine Stocks Down Following Merck's COVID-19 Pill Success
by Kinjel Shah
Stocks of several COVID-19 vaccine makers declined on Friday after Merck (MRK) released positive data for a new oral antiviral treatment for COVID-19
The Zacks Analyst Blog Highlights: Barings BDC, FirstEnergy, Pfizer and Redwood Trust
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Barings BDC, FirstEnergy, Pfizer and Redwood Trust
Take a Look at the Top-Performing Biotech ETFs YTD
by Sweta Jaiswal, FRM
The pandemic has triggered a race to introduce vaccines and treatment options, opening up investment opportunities in the biotech sector.
4 of the Best Stocks to Counter a Volatile October
by Tirthankar Chakraborty
After the September slump, more volatility may be awaiting October, which calls for investing in risk-adjusted stocks like BARINGS BDC (BBDC), FirstEnergy (FE), Pfizer (PFE) & Redwood Trust (RWT).
The Zacks Analyst Blog Highlights: Pfizer, Novo Nordisk and Sanofi
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Novo Nordisk and Sanofi
AstraZeneca (AZN) to Buy Full Stake in Rare Disease Drugmaker
by Zacks Equity Research
AstraZeneca (AZN) looks to buy full stake in Caelum Biosciences to sharpen its focus on rare-disease drugs.
Pfizer's (PFE) Prevnar 20 Plus Flu Vaccine Study Meets Goal
by Zacks Equity Research
Pfizer's (PFE) Prevnar 20 co-administered with a flu vaccine elicits non-inferior immunogenicity compared to administration of the vaccines one month apart in a late-stage study.
J&J (JNJ) Starts Phase III Study on RSV Vaccine in Older Adults
by Zacks Equity Research
J&J (JNJ) starts the phase III study on its RSV vaccine candidate in adults aged 60 years and above.
3 Big Drug/Biotech Stocks to Boost Your Portfolio's Health
by Kinjel Shah
Sanofi (SNY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that are worth betting on in the current scenario.
United Airlines (UAL) to Sack Workers on Vaccine Refusal Grounds
by Zacks Equity Research
The 593 workers of United Airlines (UAL) have not applied for exemption from getting jabbed on medical or religious grounds.
5 Winning Global ETFs of First Nine Months of 2021
by Sanghamitra Saha
Global markets have rallied this year on return of the risk-on sentiments. However, rising rate worries caused occasional turmoil in the market in September.
5 Top ETF Stories of Nine Months of 2021
by Sweta Killa
We discuss some of the hot events of the first nine months of this year that influenced the market in a big way.
Pfizer (PFE) Submits COVID-19 Vaccine Data on Children to FDA
by Zacks Equity Research
Pfizer (PFE) and BioNTech plan to seek emergency use authorization for Comirnaty in children 5 to less than 12 years of age.
Glaxo's (GSK) Long-Acting Drug NDA Gets Priority Tag for PrEP
by Zacks Equity Research
Glaxo's (GSK) HIV subsidiary, ViiV Healthcare gets FDA's priority review for a new drug application for long-acting cabotegravir regimen. ViiV Healthcare signs a deal for developing ultra long-acting HIV treatment.
Sanofi (SNY) Ends mRNA COVID Vaccine Bid Despite Positive Data
by Zacks Equity Research
Sanofi (SNY) dumps development of mRNA-based COVID vaccine despite promising data from an early study. Instead, it will focus on its adjuvanted recombinant protein vaccine candidate.
Lilly's (LLY) Erbitux Gets FDA Nod for Expanded Use in CRC
by Zacks Equity Research
Eli Lilly (LLY) secures FDA approval for Erbitux combined with Pfizer's Braftovi to treat BRAF V600E mutation-positive metastatic CRC in adult patients who received prior therapy.
PFE vs. NVO: Which Stock Is the Better Value Option?
by Zacks Equity Research
PFE vs. NVO: Which Stock Is the Better Value Option?
Has Pfizer (PFE) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (PFE) Outperforming Other Medical Stocks This Year?